Trivedi Hirsh D, Lizaola Blanca, Tapper Elliot B, Bonder Alan
Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Department of Internal Medicine, St. Elizabeth's Medical Center, Brighton, Massachusetts, USA.
Frontline Gastroenterol. 2017 Jan;8(1):29-36. doi: 10.1136/flgastro-2016-100741. Epub 2016 Nov 3.
Primary biliary cholangitis (PBC) is an immunological condition that causes a significant health disturbance and dramatically reduces the quality of life for those affected with the disease. It is a potentially fatal disease that can lead to multiple hepatic and extrahepatic complications. Having adequate therapeutic interventions that can improve the course of the disease is imperative in reducing the associated morbidity and mortality. Ursodeoxycholic acid (UDCA) is the gold standard therapy. However, it has been associated with suboptimal response rates in a significant proportion of patients. Despite UDCA, approximately 35%-40% of individuals with PBC still experience a progression of the disease, leading to liver failure and requiring liver transplantation. Recent studies of new pharmacological approaches have shown beneficial outcomes. Some of these agents can now be applied to a clinical scenario. In this review article, we will outline the new and emerging treatments for PBC.
原发性胆汁性胆管炎（PBC）是一种免疫性疾病，会严重影响健康，并显著降低患者的生活质量。它是一种潜在的致命疾病，可导致多种肝脏和肝外并发症。拥有能够改善疾病进程的适当治疗干预措施对于降低相关的发病率和死亡率至关重要。熊去氧胆酸（UDCA）是标准治疗方法。然而，在相当一部分患者中，它的有效率并不理想。尽管使用了UDCA，但仍有大约35%-40%的PBC患者病情仍在进展，导致肝衰竭并需要进行肝移植。最近关于新药理学方法的研究已显示出有益的结果。其中一些药物现已可应用于临床。在这篇综述文章中，我们将概述PBC的新兴治疗方法。
